NVO - Better Weight Loss Stock: Eli Lilly or Novo Nordisk?
2023-12-12 07:30:00 ET
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have been the two best-performing large-cap pharma stocks over the past 10 years. The core reason is their strong competitive positions in type 2 diabetes and obesity care.
Lilly's leading metabolic disease therapy is tirzepatide, which is sold under the brand names Mounjaro for type 2 diabetes and Zepbound for obesity care. Bullish analysts expect this lead metabolic therapy, combined with Lilly's follow-on offerings in the space, to hit $65 billion in annual sales by 2031.
Image source: Getty Images.
For further details see:
Better Weight Loss Stock: Eli Lilly or Novo Nordisk?